Innohep Dosage
Generic name: TINZAPARIN SODIUM 20000[iU] in 1mL
Dosage form: injection, solution
Medically reviewed on October 5, 2018.
All patients should be evaluated for bleeding disorders before administration of INNOHEP®. Since coagulation parameters are unsuitable for monitoring INNOHEP® activity, routine monitoring of coagulation parameters is not required (see PRECAUTIONS, Laboratory Tests).
Adult Dosage
The recommended dose of INNOHEP® for the treatment of DVT with or without PE is 175 anti-Xa IU/kg of body weight, administered SC once daily for at least 6 days and until the patient is adequately anticoagulated with warfarin (INR at least 2.0 for two consecutive days). Warfarin sodium therapy should be initiated when appropriate (usually within 1-3 days of INNOHEP® initiation). Pregnancy has little or no influence on the pharmacokinetics of INNOHEP® and no dosing adjustment is needed for pregnancy.
As INNOHEP® may theoretically affect the PT/INR, patients receiving both INNOHEP® and warfarin should have blood for PT/INR determination drawn just prior to the next scheduled dose of INNOHEP®.
Table 8 provides INNOHEP® doses for the treatment of DVT with or without PE. It is necessary to calculate the appropriate INNOHEP® dose for patient weights not displayed in Table 8.
An appropriately calibrated syringe should be used to assure withdrawal of the correct volume of drug from INNOHEP® vials.
| DVT Treatment | |||
|---|---|---|---|
| Patient Body Weight in Pounds |
175 IU/kg SC Once Daily 20,000 IU per mL |
Patient Body Weight in Kilograms |
|
| Dose (IU) |
Amount (mL) |
||
| 68-80 | 6,000 | 0.3 | 31-36 |
| 81-94 | 7,000 | 0.35 | 37-42 |
| 95-107 | 8,000 | 0.4 | 43-48 |
| 108-118 | 9,000 | 0.45 | 49-53 |
| 119-131 | 10,000 | 0.5 | 54-59 |
| 132-144 | 11,000 | 0.55 | 60-65 |
| 145-155 | 12,000 | 0.6 | 66-70 |
| 156-168 | 13,000 | 0.65 | 71-76 |
| 169-182 | 14,000 | 0.7 | 77-82 |
| 183-195 | 15,000 | 0.75 | 83-88 |
| 196-206 | 16,000 | 0.8 | 89-93 |
| 207-219 | 17,000 | 0.85 | 94-99 |
| 220-232 | 18,000 | 0.9 | 100-105 |
| 233-243 | 19,000 | 0.95 | 106-110 |
| 244-256 | 20,000 | 1 | 111-116 |
| 257-270 | 21,000 | 1.05 | 117-122 |
| 271-283 | 22,000 | 1.1 | 123-128 |
| 284-294 | 23,000 | 1.15 | 129-133 |
| 295-307 | 24,000 | 1.2 | 134-139 |
| 308-320 | 25,000 | 1.25 | 140-145 |
| 321-331 | 26,000 | 1.3 | 146-150 |
| 332-344 | 27,000 | 1.35 | 151-156 |
| 345-358 | 28,000 | 1.4 | 157-162 |
To calculate the volume (mL) of an INNOHEP® 175 anti-Xa IU per kg SC dose for treatment of deep vein thrombosis:
- Patient weight (kg) X 0.00875 mL/kg = volume to be administered (mL) subcutaneously
Administration
INNOHEP® is a clear, colorless to slightly yellow solution, and as with other parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
INNOHEP® is administered by SC injection. It must not be administered by intramuscular or intravenous injection.
Subcutaneous Injection Technique: Patients should be lying down (supine) or sitting and INNOHEP® administered by deep SC injection. Administration should be alternated between the left and right anterolateral and left and right posterolateral abdominal wall. The injection site should be varied daily. The whole length of the needle should be introduced into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. To minimize bruising, do not rub the injection site after completion of the injection.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Innohep (tinzaparin)
- Innohep Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- 1 Review
- Drug class: heparins
